Casi Pharmaceuticals reports Q3 EPS (55c) vs. (35c) last year

Reports Q3 revenue $7.79M vs. $8.8M last year. Wei-Wu He, Chairman and CEO of CASI, said “The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company’s strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation of China’s National Medical Products Administration has approved our Clinical Trial Application for a phase 1/2 study of CID-103 in patients with chronic Immune Thrombocytopenia in China. This China study is part of the global study that was approved by the US FDA in May. Furthermore, we are making steady progress towards filing the Investigational New Drug application for Antibody-Mediated Rejection of renal allograft in the US.”